tert-butyl 4-(2,2-difluoroethyl)piperidine-1-carboxylate | 252985-87-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-(2,2-difluoroethyl)piperidine-1-carboxylate
• 英文别名: 4-(2,2-Difluoroethyl)piperidine-1-carboxylic acid tert-butyl ester
• CAS: 252985-87-8
• 化学式: C₁₂H₂₁F₂NO₂
• 分子量: 249.301
• InChiKey: LPLWYTQLIISGCV-UHFFFAOYSA-N

物化性质

• 沸点：
  288.1±15.0 °C(Predicted)
• 密度：
  1.067±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(2,2-difluoroethyl)piperidine-1-carboxylate 在 palladium on activated charcoal N-甲基吗啉 、 盐酸 、 氢气 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， -10.0~20.0 ℃ 、100.0 kPa 条件下， 反应 102.0h， 生成
  参考文献：
  名称：

  Design and Synthesis of Thrombin Inhibitors:  Analogues of MD-805 with Reduced Stereogenicity and Improved Potency

  摘要：

  Mitsubishi's MD-805, a potent and selective inhibitor of thrombin which contains four stereogenic centers, has been the starting point for an optimization program. A systematic synthetic study resulted in thrombin inhibit;ors achiral at P2 and P3 but with a 10-fold increase in potency over the original lead. A number of 4-substituted piperidines were synthesized and examined as replacements for 2-carboxy-4-methylpiperidine at P2; 4-fluoroethylpiperidine (FEP) among others provided inhibitors (e.g. 45g) of increased potency. An enantioselective route was developed to 3(R)-methyl-1,2,3,4-tetrahydroquinolinesulfonyl chloride. Inhibitors containing this enantiomerically pure P3 (42d) had similar potency to the racemic material and provided support, with modeling studies, for the preparation of the gem 3,3-disubstituted compounds. A series of inhibitors containing the novel 3,3-dimethyl-1,2,3,4-tetrahydroquinolinesulfonyl (DMTHQS) P3 (Table 5) were synthesized and showed a similar activity profile as the monomethyl series. The combination of P3-DMTHQS, PB-FEP, and P1-arginine (45g) had a K-i of 6 nM (MD-805 K-i = 85 nM). In animal models of both venous and arterial thrombosis, one inhibitor (42e) was shown to produce a dose-dependent inhibition of thrombus formation that in some situations was superior to that of MD-805.

  DOI：

  10.1021/jm9811209
• 作为产物：
  描述：

  N-Boc-4-哌啶乙醇 在 N-ethyl-N-(trifluoromethyl)ethanamine 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 18.5h， 生成 tert-butyl 4-(2,2-difluoroethyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE
  [FR] BENZOXAZÉPINES UTILISÉES COMME INHIBITEURS DE P13K/MTOR ET PROCÉDÉS D'UTILISATION ET DE FABRICATION

  摘要：

  公开号：

  WO2012071509A3

文献信息

• Silver‐Enabled General Radical Difluoromethylation Reaction with TMSCF ₂ H
  作者：Jun Yang、Shengqing Zhu、Fang Wang、Feng‐Ling Qing、Lingling Chu

  DOI：10.1002/anie.202014587

  日期：2021.2.19

  A silver‐mediated oxidative difluoromethylation of styrenes and vinyl trifluoroborates with TMSCF2H is reported for the first time. This method enables direct and facile access to CF2H‐alkenes from abundant alkenes with excellent functional‐group compatibility. Moreover, this Ag/TMSCF2H protocol could further enable a series of radical difluoromethylation reactions of a wide array of substrates, offering

  首次报道了用TMSCF 2 H对苯乙烯和三氟硼酸乙烯基酯进行银介导的氧化二氟甲基化。这种方法可以从丰富的烯烃中直接和轻松地获得CF 2 H-烯烃，并且具有出色的官能团相容性。此外，该Ag / TMSCF 2 H方案可以进一步实现一系列底物的一系列自由基二氟甲基化反应，从而为构建多样化的C-CF 2 H键提供通用和互补的平台。
• Copper-Catalyzed Decarboxylative Difluoromethylation
  作者：Xiaojun Zeng、Wenhao Yan、Samson B. Zacate、Tzu-Hsuan Chao、Xiaodong Sun、Zhi Cao、Kate G. E. Bradford、Matthew Paeth、Sam B. Tyndall、Kundi Yang、Tung-Chun Kuo、Mu-Jeng Cheng、Wei Liu

  DOI：10.1021/jacs.9b05363

  日期：2019.7.24

  We report herein a highly efficient Cu-catalyzed protocol for the conversion of aliphatic carboxylic acids to the corresponding difluoromethylated analogues. This robust, operationally simple and scalable protocol tolerates a variety of functional groups and can convert a diverse array of acid-containing complex molecules to the alkyl-CF2H products. Mechanistic studies support the involvement of alkyl

  我们在此报告了一种高效的铜催化方案，用于将脂肪族羧酸转化为相应的二氟甲基化类似物。这种稳健、操作简单且可扩展的协议可以容忍多种官能团，并且可以将各种含酸的复杂分子转化为烷基-CF2H 产品。机理研究支持烷基自由基的参与。
• [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÈPINES COMME INHIBITEURS DE MTOR ET MÉTHODES D'UTILISATION ET DE FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2010138490A1

  公开（公告）日：2010-12-02

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R1 and R2 are as defined herein, and pharmaceutically acceptable salts thereof.

  这项发明涉及 mTOR 的抑制剂及其药用盐或溶剂，以及它们的使用方法。这些抑制剂通常具有结构式，其中 R1 和 R2 的组合如本文所定义，并且其药用盐。
• [EN] BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES COMME INHIBITEURS DE PI3K/M TOR, MÉTHODES D'UTILISATION ET DE FABRICATION BENZOXAZEPINES AS INHIBITORS OF PI3K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：EXELIXIS INC

  公开号：WO2010138487A1

  公开（公告）日：2010-12-02

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  这项发明涉及式(I)的化合物：该发明提供了抑制、调节和/或调节P13K和/或mTOR的化合物，这些化合物在治疗哺乳动物的高增殖性疾病，如癌症，方面非常有用。该发明还提供了制备该化合物的方法，以及在治疗哺乳动物，特别是人类的高增殖性疾病中使用这些化合物的方法，以及含有这些化合物的药物组合物。例如，对PI3fC-α mTOR或两者都具有活性有助于其病理学和/或症状学的癌症包括乳腺癌、套细胞淋巴瘤、肾细胞癌、急性髓细胞白血病、慢性髓细胞白血病、NPM/ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。
• Copper‐Catalyzed Difluoromethylation of Alkyl Iodides Enabled by Aryl Radical Activation of Carbon–Iodine Bonds
  作者：Aijie Cai、Wenhao Yan、Chao Wang、Wei Liu

  DOI：10.1002/anie.202111993

  日期：2021.12.20

  An aryl radical activation strategy has been developed that can engage unactivated alkyl iodides in copper-catalyzed Negishi-type cross-coupling reactions. The strategy is based on the largely overlooked yet highly efficient reactivity of aryl radicals to abstract iodine atoms from alkyl iodides.

  已经开发出一种芳基自由基活化策略，可以在铜催化的 Negishi 型交叉偶联反应中使用未活化的烷基碘。该策略基于芳基自由基从烷基碘化物中提取碘原子的很大程度上被忽视但高效的反应性。